Skip to main content

Table 3 Measures of Impairment and Perception

From: Quality of life in adults with muscular dystrophy

 

DMD

BMD

LGMD

FSHD

CTRL

KEMVC (N.m)

12.6 ± 8.8 B***,LG***,F***,C***

96.6 ± 60.0 C**

98.2 ± 56.4 C*

123.6 ± 78.2

164.6 ± 55.9

CIS Severity

34.4 ± 8.7 F*,C***

33.2 ± 10.5 F**,C***

34.4 ± 10.9 C***

43.0 ± 5.3 C***

14.1 ± 6.1

VAS Pain

2.5 ± 1.6 C**

3.5 ± 2.5 C***

3.6 ± 2.8 C***

3.9 ± 2.2 C***

0.4 ± 0.7

NEADL

13.9 ± 6.0 B***,LG*,F***,C***

36.7 ± 14.4C***

29.3 ± 7.1 C***

39.4 ± 14.6C**

63.6 ± 3.1

Self-Efficacy

31.0 ± 6.2

28.3 ± 5.9

31.0 ± 5.1

30.7 ± 7.5

34.3 ± 4.3

  1. Measures of Impairment and Perception
  2. DMD Duchenne Muscular Dystrophy, BMD Beckers Muscular Dystrophy, LGMD Limb-Girdle Muscular Dystrophy, FSHD Facioscapulohumeral Muscular Dystrophy, CIS Checklist Individual Strength, VAS Visual Analog Scale, KEMVC Knee Extension Maximal Voluntary Contraction, N.m Newton Metres, NEADL Nottingham Extended Activities of Daily Living; B denotes significant difference from BMD; LG denotes significant difference from LGMD; F denotes significant difference from FSHD; C denotes significant difference from CTRL; * denotes significance P < .05; ** denotes significance P < .01; *** denotes P < .001
Back to article page

Health and Quality of Life Outcomes

ISSN: 1477-7525

Contact us